Greene Warner C, Debyser Zeger, Ikeda Yasuhiro, Freed Eric O, Stephens Edward, Yonemoto Wes, Buckheit Robert W, Esté José A, Cihlar Tomas
Gladstone Institute of Virology and Immunology, San Francisco, CA, USA.
Antiviral Res. 2008 Dec;80(3):251-65. doi: 10.1016/j.antiviral.2008.08.003. Epub 2008 Sep 30.
There are currently 25 drugs belonging to 6 different inhibitor classes approved for the treatment of human immunodeficiency virus (HIV) infection. However, new anti-HIV agents are still needed to confront the emergence of drug resistance and various adverse effects associated with long-term use of antiretroviral therapy. The 21st International Conference on Antiviral Research, held in April 2008 in Montreal, Canada, therefore featured a special session focused on novel targets for HIV therapy. The session included presentations by world-renowned experts in HIV virology and covered a diverse array of potential targets for the development of new classes of HIV therapies. This review contains concise summaries of discussed topics that included Vif-APOBEC3G, LEDGF/p75, TRIM 5alpha, virus assembly and maturation, and Vpu. The described viral and host factors represent some of the most noted examples of recent scientific breakthroughs that are opening unexplored avenues to novel anti-HIV target discovery and validation, and should feed the antiretroviral drug development pipeline in the near future.
目前有25种属于6种不同抑制剂类别的药物被批准用于治疗人类免疫缺陷病毒（HIV）感染。然而，仍需要新的抗HIV药物来应对耐药性的出现以及与长期使用抗逆转录病毒疗法相关的各种不良反应。因此，2008年4月在加拿大蒙特利尔举行的第21届国际抗病毒研究会议设有一个特别会议，重点关注HIV治疗的新靶点。该会议包括HIV病毒学领域世界知名专家的演讲，并涵盖了开发新型HIV疗法的一系列潜在靶点。本综述简要总结了所讨论的主题，包括Vif-APOBEC3G、LEDGF/p75、TRIM 5α、病毒组装与成熟以及Vpu。所描述的病毒和宿主因子代表了近期一些最显著的科学突破实例，这些突破为发现和验证新的抗HIV靶点开辟了未探索的途径，并有望在不久的将来为抗逆转录病毒药物研发提供助力。
